Viridian Therapeutics disclosed topline Phase 3 results for elegrobart (formerly VRDN-003) in active thyroid eye disease, reporting that the subcutaneous, half-life-extended IGF-1R antibody met a primary endpoint. The trial evaluated every-four-weeks and every-eight-weeks dosing versus placebo in 132 patients. Viridian reported a proptosis responder rate of 54% for the monthly regimen versus 18% for placebo at week 24, alongside mean proptosis reduction of 2.33 mm versus 0.81 mm. The company also reported higher complete resolution rates of diplopia for treated cohorts. Despite the endpoint achievement, the coverage notes that investors remained focused on commercial differentiation versus established therapy teprotumumab (Tepezza), including cross-trial comparisons and competitive feasibility questions. The readout keeps elegrobart in the regulatory conversation for a patient population with limited treatment options and underscores how pivotal trial design and differentiation are increasingly scrutinized alongside endpoint success.